MLL leukemia and future treatment strategies

Area of Science:

• * Molecular biology
• * Genetics
• * Oncology

Background:

• * Chromosomal rearrangements involving the MLL gene are implicated in various acute leukemias.
• * Over 200 MLL gene fusions have been identified, all characterized by genetic disruption of the MLL gene.
• * MLL fusions result in aberrant MLL-X proteins that drive oncogenesis through ectopic gene transcription.

Purpose of the Study:

• * To review the molecular mechanisms of MLL fusion proteins in leukemia.
• * To discuss targeted therapeutic strategies aimed at inhibiting MLL fusion proteins.
• * To critically evaluate recent efforts in developing inhibitors and their modes of action.

Main Methods:

• * Comprehensive literature review of MLL gene rearrangements and fusion proteins.
• * Analysis of molecular mechanisms underlying MLL fusion oncogenesis.
• * Examination of current therapeutic strategies and inhibitor development.

Main Results:

• * MLL-X fusion proteins recruit nuclear factors, leading to ectopic gene transcription.
• * Frequent MLL fusions recruit the AF4 complex, including P-TEFb, BRD4, and DOT1L.
• * Reciprocal X-MLL fusions possess distinct domains (PHD, SET) and interact with different proteins, with functional consequences largely unelucidated.

Conclusions:

• * Understanding MLL fusion protein function is crucial for developing targeted therapies.
• * Inhibiting the oncogenic activity of MLL fusion proteins is a promising therapeutic avenue.
• * Ongoing research focuses on developing and evaluating novel inhibitors for MLL-driven leukemias.